Communiqués Exousia Bio, Inc.

Actions

Marché Fermé - OTC Markets Autres places de cotation 19:57:06 16/06/2026			Varia. 5j.	Varia. 1 janv.
0,4381 ^USD	+21,69%		-.--%	+39,97%

16/06	Exousia Bio, Inc. publie ses resultats pour le troisieme trimestre et les neuf mois clos le 28 fevrier 2026	CI
17/03	LAMY publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 novembre 2025	CI

16/06	LAMY : Quarterly Report for Quarter Ending February 28, 2026 (Form 10-Q)	PU
17/03	LAMY : Quarterly Report for Quarter Ending November 30, 2025 (Form 10-Q)	PU
04/12	Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview	AQ
02/12	LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.	AQ
17/11	LAMY : Quarterly Report for Quarter Ending August 31, 2025 (Form 10-Q)	PU
17/10/25	LAMY : Annual Report for Fiscal Year Ending May 31, 2025 (Form 10-K)	PU
25/04/25	LAMY Inc. Accelerates Strategic Upgrades, Deepens Global Presence and Technological Innovation	AQ
22/04/25	LAMY Unveils GenZ Financial Literacy Initiative Powered by User-Generated Content and Creator Economy Tools	AQ
04/04/25	LAMY Forms Strategic Partnership with a Renowned Family, Pioneering New Integration of NFTs and Education	AQ
14/03/25	LAMY Discusses The Smart Education Market Entering a Golden Era of Growth	AQ
17/12/24	LAMY : Changes in Control Form 8 K	PU
30/11/-1	Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms	AQ
30/11/-1	Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value	AQ